Introduction
Malignant gliomas, which consist of high-grade anaplastic astrocytomas and glioblastoma multiforme, are the most common adult intracranial tumors and account for approximately 20% of childhood primary brain tumors. Despite surgery, radiotherapy and chemotherapy, up to 80% of patients succumb to local tumor recurrence within 2 years of diagnosis. [1] [2] [3] [4] [5] Preclinical gene therapy studies have demonstrated the potential to improve local tumor control through the delivery of therapeutic DNA constructs that encode cytotoxic or immunomodulating proteins. [6] [7] [8] When nonreplicating adenoviruses or retroviruses encoding herpes simplex virus thymidine kinase were used as gene therapy vectors in glioma xenograft models, tumor regression was observed. [9] [10] [11] In recent investigations, the 5Ј regulatory region of the early growth response gene (Egr-1) was ligated upstream of the cDNA of tumor necrosis factor-␣ (TNF-␣). 12 Ad5 was used to deliver the Egr-TNF construct (Ad.Egr-TNF) to human epidermoid carcinoma (SQ-20B) xenografts because TNF-␣ has been shown to be directly cytotoxic to SQ-20B cells in vitro. The combination of fractionated radiation and intratumoral Ad.Egr-TNF resulted in greater tumor regression and growth delay compared to xenografts treated with either Ad.Egr-TNF alone or radiation alone. 13 The observed interaction between TNF-␣ gene therapy and irradiation in SQ-20B xenografts involved an increase in local occlusion of tumor microvessels and larger areas of necrosis when compared with treatment with either modality alone. 14 To establish a preclinical model for gene therapy and therapeutic radiation in gliomas, we administered intratumoral Ad.Egr-TNF and local, fractionated radiation to human malignant glioma (D54) xenografts growing in athymic nude mice. We observed that despite the lack of in vitro cytotoxic interaction between TNF-␣ and radiation in glioma cells, Ad.Egr-TNF and radiation interacted to enhance tumor regression and promote tumor vascular thrombosis.
Results
Clonogenic survival of D54 cells treated with TNF␣ and radiation We evaluated clonogenic survival of D54 cell cultures which were exposed to increasing concentrations of human recombinant TNF-␣. A modest reduction in the mean surviving fraction (0.676 ± 0.173; range 0.619-0.776) was observed in D54 cells exposed to TNF-␣ doses ranging from 10 to 1000 ng/ml when compared with control cells. To determine whether a cytotoxic interaction existed between TNF-␣ and radiation, mean survival fractions were evaluated following administration of 294 100 ng/ml of TNF-␣ and 0, 1, 3, 5, 7 or 9 Gy doses of radiation. The D 0 of irradiated D54 cells was 0.93 Gy (n = 1.95) compared with the D 0 of cells exposed to TNF-␣ (1.25 Gy, n = 0.74). Survival analyses suggested no cytotoxic interaction between TNF-␣ and radiation in D54 cells (Figure 1 ).
Ad.Egr-TNF and radiation in D54 xenografts D54 glioma xenografts were treated with intratumoral injection of Ad.Egr.TNF and fractionated radiation (5 Gy per day, 4 days per week, total dose of 30 Gy). Mice were killed at day 60 or when tumor volumes exceeded 2000 mm 3 . Untreated control tumors reached a mean volume of 2000 mm 3 by day 24. Data were pooled from two separate experiments (n = 70). No spontaneous tumor regressions were observed. Complete regression rates were defined as the number of measurable tumor volumes equal to 0 mm 3 divided by the number of tumors in each treatment group by day 60. Seventy-one per cent (eight of 11) of tumors treated with Ad.Egr-TNF and radiation completely regressed by day 60. Complete regression rates in tumors receiving combined treatment were significantly higher compared to radiation alone (one of 13, 7.4%; P = 0.006), Ad.null plus radiation (none of 13, 0%; P = 0.002), and Ad.Egr-TNF alone (none of 7, 0%; P = 0.012).
Data for each treatment group were calculated as the tern with tumor doubling by day 20, a 90% tumor reduction by day 38, and resumed growth and doubling by day 56.
No evidence of systemic toxicity was apparent in any of the mice receiving a combination of adenoviral gene therapy and radiation (n = 70). All mice demonstrated normal activity and had normal skin turgor. By day 30, the skin of the right hindlimbs treated with Ad.Egr-TNF and radiation demonstrated small areas of necrosis corresponding to the area where the Ad.Egr-TNF vector had been injected. By day 60, these treated right hindlimbs appeared normal in size and color compared with corresponding untreated left hindlimbs.
Adenovirus in situ hybridization and TNF-␣ protein detection Paraffin-embedded tumor sections treated with Ad.null or Ad.Egr-TNF and radiation were evaluated to determine the distribution of the adenoviral vector in D54 xenografts. Light microscopy (× 160) visualizing the adenoviral probe confirmed the presence of Ad.Egr-TNF along the needle track ( Figure 3a) . The expression of TNF-␣ protein was determined using an ELISA specific for human TNF-␣. No TNF-␣ protein was detected in control D54 xenografts, or in xenografts treated with irradiation (5 and 20 Gy) or Ad.null with and without radiation. However, human TNF-␣ was present in tumors treated with Ad.Egr-TNF. At day 4, TNF-␣ concentrations reached 345 ± 178 pg.mg protein and increased to 1033 ± 201 pg/mg protein by day 7.
Thrombosis and necrosis in D54 xenografts
We evaluated hematoxylin and eosin-stained D54 tumor sections for tumor vascular thrombosis and necrosis at days 4 and 7. Xenografts treated with Ad.Egr-TNF and radiation were compared with xenografts which were untreated, or treated with radiation alone, Ad.Egr-TNF alone or Ad.null and radiation. Histopathologic differences were noted between untreated tumors (Figure 3b ) and tumors treated with Ad.Egr-TNF and radiation at both day 4 ( Figure 3c ) and day 7 (Figure 3d ). Inflammatory infiltration was also noted in sections from xenografts receiving combined treatment with Ad.Egr-TNF and radiation.
Percentage thrombosis per 10 high power fields (×400) was defined as the ratio between thrombosed vessels and the total number of patent and thrombosed vessels. At day 4, there was a significant increase in thrombosis in tumors treated with Ad.Egr-TNF and radiation (60 ± 16%, P Ͻ 0.005) when compared with untreated controls (0%), xenografts treated with radiation alone (25 ± 13%), Ad.Egr-TNF alone (0%) and Ad.null with radiation (0%) ( Table 1 ). Figure 3c is a representative tumor section from a xenograft excised on day 4 following treatment with Ad.Egr-TNF and radiation. A thrombotic vessel surrounded by inflammatory cells can be seen. Percentage necrosis was defined as the average of the percentage area of necrosis in 10 high-powered fields (×400). Figure 3d shows a representative necrotic area in a D54 tumor treated with Ad.Egr-TNF and radiation at day 7. Significant differences in percentage necrosis were observed at day 7 between tumors treated with Ad.Egr-TNF and radiation (32 ± 12.6%; P Ͻ 0.012) when compared with untreated (0.02 ± 0.01%) and irradiated tumors (8 ± 4.6%), tumors treated with Ad.Egr-TNF alone (0.05 ± 0.04%) and tumors treated with Ad.null and radiation (3 ± 3%) ( Table 1) .
Discussion
These studies investigated the interactive effects of adenoviral TNF-␣ gene therapy and radiotherapy in D54, a human malignant glioma xenograft. After administration of Ad.Egr-TNF and radiation, D54 xenografts showed significant tumor regression, tumor growth delay, and reduction in median fractional tumor volumes by day 60, compared with xenografts treated with either agent alone or Ad.null with radiation. The antitumor effects produced by Ad.Egr-TNF and radiation appear to be more than additive since neither treatment alone produced significant growth inhibition. Histopathologic analyses of xenografts treated with both agents revealed increased tumor thrombosis and necrosis compared with all other treatments. Since our in vitro findings demonstrated a lack of direct cytotoxic interaction between TNF-␣ and radiation, the D54 tumor regression observed following combined treatment with Ad.Egr-TNF and radiation suggested antitumor activity to be mediated in part by thrombosis of tumor vasculature.
Human TNF-␣ binds to murine TNF-␣ 55 kDa receptors on murine endothelium thereby mediating neutrophil adhesion and endothelial cell activation. [15] [16] [17] Tumor vascular destruction has been reported in multiple xenograft models in mice treated with human TNF-␣. [18] [19] [20] Low concentrations of TNF-␣ have been shown to promote proliferation of endothelial cells 21, 22 while higher concentrations are cytotoxic to, and result in apoptosis of, endothelial cells both in vitro and in vivo. [21] [22] [23] [24] Apoptosis of endothelial cells can cause the loss of endothelial cell anticoagulant surface components and increased expression of phosphatidylserine leading to a procoagulant microenvironment. 25 In addition, TNF-␣ has been observed to promote a procoagulant state in vivo by directly inhibiting thrombomodulin production 26 and enhancing tissue factor synthesis. 27, 28 Similarly, ionizing radiation has been associated with a procoagulant state 29, 30 as well as endothelial apoptosis. 31 Free radical production following exposure to radiation 32 and other agents such as melphalan, has also been shown to cause thrombosis of tumor vasculature. 33 In this study, the vascular thrombosis that was observed following combined treatment could have resulted from either endothelial damage with activation of procoagulants or direct activation of coagulation mechanisms.
Although Ad5 did not transfect most glioma cells in our xenografts, the presence of TNF-␣ in excised tumors suggested that the antitumor properties of this vector were possibly achieved through a 'bystander' effect of diffusible, toxic, protein products. 34 This 'bystander' effect may have been amplified by the fact that a patent blood vessel in a malignant glioma xenograft can supply between 10 3 and 10 5 tumor cells. To determine whether this vascular response is universal, additional glioma cell lines would need to be tested. Since malignant gliomas are characterized by neovascular formation, adenoviral TNF-␣ gene therapy combined with radiotherapy may have potential clinical application to improve tumor control through alterations of the tumor microvasculature.
Materials and methods

Cell cultures
Human malignant glioma cells (D54) (Duke University Medical Center, Durham, NC, USA) were cultured as a monolayer in 50% Dulbecco's modified Eagle's medium (GIBCO, Grand Island, NY, USA), 50% F-12 medium (GIBCO), 7% fetal calf serum and 1% penicillin/ streptomycin. The cell line was incubated at 37°C in 7% carbon dioxide.
Clonogenic survival D54 cells were grown to 90% confluence in 60 mm dishes with 7% serum medium. Two different clonogenic survival assays were performed in triplicate. The first assay was performed to examine the clonogenic survival of D54 glioma cells in the presence of different concentrations of human recombinant TNF-␣. D54 glioma cells grown in 3 ml of serum medium, were exposed to either 10 ng/ml, 100 ng/ml or 1000 ng/ml of TNF-␣ (Genzyme, Boston, MA, USA) for 24 h. Treated cells were then harvested by removing the medium and adding 0.25% versene followed by 0.25% trypsin. After harvesting, 10% serum medium was added to the cell suspension to inactivate 81.0 ± 11.0** 32.0 ± 12.6* Histopathology of D54 xenografts following treatment with Ad.Egr-TNF and radiation. D54 xenografts growing in the right hindlimb of nude mice were removed at day 4 and day 7, fixed and prepared for examination by light microscopy. Xenografts were evaluated for the percentage of necrosis (×400). Significance was determined using the Kruskal-Wallis test. Tumor sections were also scored for the ratio of thrombosed to total number of blood vessels (×400). Significance was determined using one-way ANOVA. *P Ͻ 0.05; **P Ͻ 0.005. the trypsin. Cell count was determined using a hemocytometer and cells were plated as described below. The second assay was performed to examine the radiation survival curves of D54 glioma cells with and without TNF-␣. D54 glioma cells grown in 3 ml of medium, were treated with 100 ng/ml of human recombinant TNF-␣ for 24 h. Control cells and cells exposed to TNF-␣ were irradiated at doses of 0, 1, 3, 5, 7 or 9 Gy using a Maxitron generator, operating at 250 kV, 26 mA at a rate of 1.88 Gy/min. One hour following irradiation, all cells, including controls, were harvested with versene and trypsin, and the cell count was determined as described above. All treated and control glioma cells were plated in 100 mm dishes with 8 ml of growth medium at densities of 10 2 , 10 3 , 5 × 10 , 10 5 cells. Within 10-14 days, dishes were washed three times with 8% normal saline and the colonies were stained with crystal violet. The number of control colonies was counted and compared with the number of control cells plated to establish plating efficiency. Clonogenic survival rate was calculated as the average of the number of treated colonies divided by the number of treated cells plated. The clonogenic survival rate was divided by the plating efficiency to determine the mean survival fraction. The standard error of the mean (s.e.m.) for each treatment group was calculated from three individual experiments. 35 Significance was determined using the Kruskal-Wallis test. 36 Treatment of D54 xenografts D54 cells were grown to 90% confluence in 150 mm flasks. After harvesting with versene and trypsin as described above, the cells were washed three times with sterile phosphate buffer solution (PBS) (Sigma, St Louis, MO, USA) and counted using a hemocytometer. After centrifugation, 1 × 10 7 D54 glioma cells/100 l PBS were injected subcutaneously into the right hindlimbs of female, athymic nude mice (Fredrick Cancer Research Institute, Boston, MS, USA). Tumors were measured biweekly with vernier calipers and volumes were calculated using the formula (length × width × height/2), which is derived from the formula for an ellipsoid (d3/6). When the tumors reached a mean volume of 252.1 ± 28.6 mm 3 , treatment was initiated (day 0). D54 xenografts were injected with 10 l of 2 × 10 8 plaque-forming unit (p.f.u.) Ad.Egr-TNF or the null vector (Ad.null) (GenVec, Rockville, MD, USA), 14 twice a week for 2 weeks. Both the Ad.null and Ad.Egr.TNF vector were constructed by recombination using the replication-deficient adenovirus type 5 (Ad5). 37 Control tumors were not injected. Four hours after injection, mice were immobilized in individual lucite chambers and the bodies were shielded with lead except for the tumor bearing hind limbs. Xenografts were irradiated, 5 Gy per day, 4 days per week, to a total dose of 30 Gy using a Maxitron generator, operating at 150 kV, 30 mA, at a rate of 1.88 Gy/min. Tumor volumes were determined biweekly as described. Xenografts were treated with 30 Gy alone, Ad.Egr-TNF with and without radiation, or Ad.null plus 30 Gy. Control tumors were untreated.
Complete regression was defined as a measured tumor volume equal to 0 mm 3 by day 60. Complete regression rates (the number of tumor volumes equal to zero divided by the number of tumors per treatment group) were analyzed using one-sided Fisher's exact test. 38 To account for variations of initial tumor volumes within treatment groups, fractional tumor volume was calculated as the percentage of original volume at day 0. Data were graphed as mean fractional tumor volume ± s.e.m. for each treatment group. Mean fractional tumor volumes at day 60 were analyzed using the Mann-Whitney rank sum test for pair-wise analysis. 39 Tumor doubling time was defined as the time in days until the tumor first doubled in size. This value was extrapolated from log/linear plots of the mean fractional tumor volumes converted to log base two versus days which yielded an approximately straight line over 60 days. The inverses of the slopes of these lines were interpreted as the time in days required for the tumor to double in size from its day 0 volume. The Mann-Whitney rank sum test was used to compare doubling times across treatment groups. 39 The Bonferroni method was used to adjust for the effect of multiple comparisons in all statistical analyses. 35 
TNF-␣ protein in D54 xenografts
To examine the presence of endogenous human TNF-␣ in untreated xenografts and in xenografts following treatment, human TNF-␣ concentration was determined by ELISA. D54 control xenografts and xenografts treated with radiation alone, Ad.Egr-TNF alone, Ad.Egr-TNF with radiation or Ad.null with radiation, were excised, placed in tubes, and quick-frozen in liquid nitrogen at day 4 and day 7 (n = 8). Tumors were then homogenized in 500 l of sodium chloride/Tris buffer, pH 7.5, containing EDTA, dithiothreitol, and protease inhibitors using a Brinkman Polytron (Kinematica AG, Littau, Switzerland). Homogenates underwent four cycles of freezing in liquid nitrogen and thawing in a 37°C water bath. Samples were centrifuged for 5 min at 10 000 g and the supernatant was assayed for TNF-␣ with a Quantikine ELISA (R & D Systems, Minneapolis, MN, USA). Protein content was determined by the Bio-Rad Protein Micro Assay (BioRad, Hercules, CA, USA). TNF-␣ concentrations are reported as pg per mg protein.
Histopathological analyses and in situ hybridization
Two xenografts from each treatment group, including untreated control, radiation alone, Ad.Egr-TNF alone, Ad.null and radiation or Ad.Egr-TNF with radiation, were excised at days 4 and 7 (n = 10). Tumors were fixed in 10% neutral buffered formalin. Tumors were then trimmed, processed in a Tissue Tek II tissue processor (Miles Scientific Elkhart, IN, USA), and embedded in paraffin. Sections 5 m thick were mounted, baked, cleared in xylene, and hydrated through descending alcohol series and distilled water. Sections were stained with hematoxylin and eosin and examined by light microscopy.
All slides were read by investigators blinded to the treatment groups. Due to the variability in tumor size, the percentage of thrombosis was calculated as the number of thrombotic vessels divided by the number of total patent and thrombosed vessels, averaged from 10 high powered fields (×400) per tumor. Blood vessels were identified by their characteristic endothelial lining and visible intraluminal erythrocytes. Thrombosis was defined as an organized clot which obstructed the lumen of the vessel. Sections were also evaluated for percentage of necrosis, defined as the area of necrosis, averaged in 10 high powered fields (×400) per tumor. Data are reported as the average of 10 high powered fields ± s.e.m. in two tumors per treatment group at days 4 and 7. Significance was determined using Kruskal-Wallis test 36 and one-way analysis of variance (ANOVA). 35 Tumor sections were evaluated for the presence of the adenoviral vector by in situ hybridization which was performed on a Ventana Gen 11 automated immunohistochemistry and in situ system (Ventana Medical Systems, Tucson, AZ, USA). Five micron paraffin-embedded tumor sections were mounted on to teflon-coated target slides (Ventana Medical Systems), baked at 60°C for 1 h, cleared in xylene, and hydrated through a descending alcohol series. A biotinylated probe prepared by nick translating cloned Ad5 DNA fragments (Enzo Diagnostic, Farmingdale, NY, USA) was used to detect the presence of adenoviral DNA. The avidin-AP detection system employing nitroblue tetrazolium substrate produces a blue-black reaction product in adenovirus-infected cells. Slides were counterstained with nuclear fast red.
